Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323824 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5315326 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL1172743 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL3359435 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL2034678 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL5217474 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL323823 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| SCHEMBL4126470 | 1.00 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089207 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD | |
| Hydrochloric Acid SCHEMBL5089203 | 0.98 | FFAR1 (0.68) | FFAR1HDAC4ALDH1A1SLC9A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | Beijing Changping Laboratory (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4512803-A1 | GPCR REGULATOR AND USE THEREOF | Beijing Changping Laboratory (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023202578-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903562-A | GPCR modulators and uses thereof | 北京昌平实验室 | 2023-10-20 | — | — | CN | disclosed |
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | CHRNA7, CHRNA10, CHRNA5 | FFAR1 556/4885HDAC4 1194/4885ALDH1A1 708/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FFAR1 3640/4885HDAC4 1183/4885ALDH1A1 1435/4885 |
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | ARRB1, GPR3, GPR4 | FFAR1 33/4885HDAC4 1174/4885ALDH1A1 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.